company background image
MAAT logo

MaaT Pharma ENXTPA:MAAT Stock Report

Last Price

€9.32

Market Cap

€108.3m

7D

0.6%

1Y

-9.5%

Updated

26 Mar, 2024

Data

Company Financials +

MaaT Pharma SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MaaT Pharma
Historical stock prices
Current Share Price€9.32
52 Week High€10.60
52 Week Low€4.50
Beta0.21
1 Month Change6.88%
3 Month Change30.17%
1 Year Change-9.51%
3 Year Changen/a
5 Year Changen/a
Change since IPO-33.19%

Recent News & Updates

Recent updates

Shareholder Returns

MAATFR BiotechsFR Market
7D0.6%-0.2%-0.4%
1Y-9.5%-1.8%10.6%

Return vs Industry: MAAT underperformed the French Biotechs industry which returned -2.2% over the past year.

Return vs Market: MAAT underperformed the French Market which returned 10.1% over the past year.

Price Volatility

Is MAAT's price volatile compared to industry and market?
MAAT volatility
MAAT Average Weekly Movement8.9%
Biotechs Industry Average Movement5.8%
Market Average Movement4.3%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market2.2%

Stable Share Price: MAAT's share price has been volatile over the past 3 months.

Volatility Over Time: MAAT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
201451Herve Affagardhttps://www.maatpharma.com

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

MaaT Pharma SA Fundamentals Summary

How do MaaT Pharma's earnings and revenue compare to its market cap?
MAAT fundamental statistics
Market cap€108.27m
Earnings (TTM)-€14.73m
Revenue (TTM)€2.31m

46.8x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MAAT income statement (TTM)
Revenue€2.31m
Cost of Revenue€854.00k
Gross Profit€1.46m
Other Expenses€16.19m
Earnings-€14.73m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-1.27
Gross Margin63.09%
Net Profit Margin-636.60%
Debt/Equity Ratio39.7%

How did MAAT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.